Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H30O2 |
Molecular Weight | 314.4617 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
InChI
InChIKey=QHMBSVQNZZTUGM-ZWKOTPCHSA-N
InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1
Molecular Formula | C21H30O2 |
Molecular Weight | 314.4617 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24854329 | https://www.gwpharm.com/products-pipeline
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24854329 | https://www.gwpharm.com/products-pipeline
Cannabidiol is the major nonpsychoactive ingredient in cannabis. Cannabidiol demonstrates a range of effects that may be therapeutically useful, including anti-seizure, antioxidant, neuroprotective, anti-inflammatory, analgesic, anti-tumor, anti-psychotic, and anti-anxiety properties. Exact mechanism of action of cannabidiol is not known, but may include effects on the orphan G-protein-coupled receptor GPR55; the transient receptor potential of vanilloid type-1 channel; the 5-HT1a receptor; and the α3 glycine receptors. GW Pharmaceuticals successfully developed the world’s first prescription medicine derived from the cannabis plant, Sativex® (buccal spray containing delta-9-tetrahydrocannabinol and cannabidiol) now approved in over 29 countries outside of the United States for the treatment of spasticity due to Multiple Sclerosis. GW Pharmaceuticals is developing Epidiolex® (a liquid formulation of pure plant-derived cannabidiol) for certain rare and severe early-onset, drug-resistant epilepsy syndromes.
Originator
Sources: Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc. 1940;62:196-200. | Mechoulam R, Shvo Y. Hashish. 1. Structure of Cannabidiol. Tetrahedron. 1963;19(12):2073-8
Curator's Comment: Although cannabidiol was isolated from marijuana extract in 1940 by Adams et al., for almost 25 years no further work has been reported, except for a few early works about its isolation. Only in 1963 its exact chemical structure was elucidated by Mechoulam and Shvo. https://www.ncbi.nlm.nih.gov/pubmed/18833429
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16258853 |
|||
Target ID: CHEMBL4794 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11606325 |
3.2 µM [EC50] | ||
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27754480 |
11.0 nM [Ki] | ||
Target ID: CHEMBL1075322 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17876302 |
445.0 nM [IC50] | ||
Target ID: CHEMBL1075092 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22585736 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | SATIVEX Approved UseSativex is used in multiple sclerosis (MS) to improve symptoms related to muscle stiffness. This is also called “spasticity”. Spasticity means there is an increase in ‘muscle tone’ which makes the muscles feel more stiff or rigid. This means it is more difficult than normal to move the muscle. Sativex is used when other medicines have not helped your muscle stiffness. |
|||
Primary | SATIVEX Approved UseSATIVEX® buccal spray is indicated as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain. |
|||
Primary | EPIDIOLEX Approved UseUnknown |
|||
Primary | EPIDIOLEX Approved UseUnknown |
|||
Primary | EPIDIOLEX Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
330.3 ng/mL |
750 mg 2 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
541.2 ng/mL |
1500 mg 2 times / day multiple, oral dose: 1500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
292.4 ng/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
327 ng/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
782 ng/mL |
6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1588 ng/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1745 ng × h/mL |
750 mg 2 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3236 ng × h/mL |
1500 mg 2 times / day multiple, oral dose: 1500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1618 ng × h/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2198 ng × h/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3900 ng × h/mL |
6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8670 ng × h/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
56.41 h |
750 mg 2 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
60.54 h |
1500 mg 2 times / day multiple, oral dose: 1500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
14.43 h |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
15.42 h |
6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6% |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6% |
6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Disc. AE: Transaminases increased... Other AEs: Transaminases increased, Decreased appetite... AEs leading to discontinuation/dose reduction: Transaminases increased (1.3%) Other AEs:Transaminases increased (8%) Sources: Decreased appetite (16%) Diarrhea (9%) Weight decreased (3%) Abdominal discomfort (3%) Somnolence (23%) Sedation (3%) Lethargy (4%) Fatigue (11%) Malaise (11%) Asthenia (11%) Irritability (9%) Agitation (9%) Insomnia (11%) Sleep disorder (11%) Poor quality sleep (11%) Aggression (3%) Anger (3%) Drooling (1%) Salivary hypersecretion (1%) Gait disturbance (3%) Infection viral (7%) Pneumonia (8%) Fungal infection (1%) Infection NOS (25%) Rash (7%) Hypoxia (3%) Respiratory failure (3%) |
20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Disc. AE: Transaminases increased... Other AEs: Transaminases increased, Decreased appetite... AEs leading to discontinuation/dose reduction: Transaminases increased (5.9%) Other AEs:Transaminases increased (16%) Sources: Decreased appetite (22%) Diarrhea (20%) Weight decreased (5%) Abdominal discomfort (3%) Somnolence (25%) Sedation (6%) Lethargy (8%) Fatigue (12%) Malaise (12%) Asthenia (12%) Irritability (5%) Agitation (5%) Aggression (5%) Anger (5%) Drooling (4%) Salivary hypersecretion (4%) Gait disturbance (2%) Infection viral (11%) Pneumonia (5%) Fungal infection (3%) Infection NOS (21%) Rash (13%) Hypoxia (3%) Gastroenteritis (4%) Insomnia (5%) Sleep disorder (5%) Poor quality sleep (5%) Respiratory failure (3%) |
50 mg/kg/day 1 times / day multiple, oral Dose: 50 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 50 mg/kg/day, 1 times / day Sources: |
healthy, adult n = 5 Health Status: healthy Age Group: adult Population Size: 5 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Drooling | 1% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Fungal infection | 1% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Salivary hypersecretion | 1% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Transaminases increased | 1.3% Disc. AE |
10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Asthenia | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Fatigue | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Insomnia | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Malaise | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Poor quality sleep | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Sleep disorder | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Decreased appetite | 16% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Somnolence | 23% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Infection NOS | 25% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Abdominal discomfort | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Aggression | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Anger | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Gait disturbance | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Hypoxia | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Respiratory failure | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Sedation | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Weight decreased | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Lethargy | 4% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Infection viral | 7% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Rash | 7% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Pneumonia | 8% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Transaminases increased | 8% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Agitation | 9% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Diarrhea | 9% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Irritability | 9% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Infection viral | 11% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Asthenia | 12% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Fatigue | 12% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Malaise | 12% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Rash | 13% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Transaminases increased | 16% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Gait disturbance | 2% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Diarrhea | 20% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Infection NOS | 21% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Decreased appetite | 22% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Somnolence | 25% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Abdominal discomfort | 3% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Fungal infection | 3% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Hypoxia | 3% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Respiratory failure | 3% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Drooling | 4% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Gastroenteritis | 4% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Salivary hypersecretion | 4% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Aggression | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Agitation | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Anger | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Insomnia | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Irritability | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Pneumonia | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Poor quality sleep | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Sleep disorder | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Weight decreased | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Transaminases increased | 5.9% Disc. AE |
20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Sedation | 6% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Lethargy | 8% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000PharmR.pdf#page=20 Page: 20.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. | 1999 Nov 23 |
|
Cannabinoid-induced alterations in brain disposition of drugs of abuse. | 2001 Jun 1 |
|
Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. | 2001 Oct |
|
Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. | 2001 Sep 28 |
|
Medicinal use of cannabis: history and current status. | 2001 Summer |
|
The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. | 2001 Summer |
|
Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. | 2002 Apr 16 |
|
Novel 1',1'-chain substituted Delta(8)-tetrahydrocannabinols. | 2002 Dec 16 |
|
Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. | 2002 Dec 31 |
|
(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. | 2002 Dec 5 |
|
CB(1) receptor antagonist SR141716A inhibits Ca(2+)-induced relaxation in CB(1) receptor-deficient mice. | 2002 Feb |
|
DNA fingerprinting of Cannabis sativa using inter-simple sequence repeat (ISSR) amplification. | 2002 Jan |
|
Cannabidiol: an overview of some pharmacological aspects. | 2002 Nov |
|
Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. | 2002 Nov 15 |
|
Automated headspace solid-phase dynamic extraction for the determination of cannabinoids in hair samples. | 2003 Apr 23 |
|
Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. | 2003 Dec 12 |
|
Nonpsychotropic cannabinoid receptors regulate microglial cell migration. | 2003 Feb 15 |
|
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. | 2003 Feb 25 |
|
[Weather-induced changes in cannabinoid content of hair]. | 2003 Jan-Feb |
|
Simultaneous detection of some drugs of abuse in saliva samples by SPME technique. | 2003 Jun 24 |
|
Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. | 2003 Mar |
|
Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. | 2003 Nov |
|
G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. | 2003 Nov 14 |
|
Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. | 2003 Sep |
|
Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al. | 2004 Dec |
|
Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. | 2004 Dec |
|
(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. | 2004 Dec 15 |
|
Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. | 2004 Jun |
|
Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol. | 2004 Mar |
|
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. | 2004 Mar |
|
6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. | 2004 Mar 8 |
|
Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. | 2004 Oct 25 |
|
Cannabis (marijuana) contamination of United States and foreign paper currency. | 2004 Sep |
|
Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. | 2005 Apr |
|
Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. | 2005 Aug |
|
The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. | 2005 Feb |
|
Marijuana extracts possess the effects like the endocrine disrupting chemicals. | 2005 Jan 31 |
|
Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors. | 2005 Mar 21 |
|
Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits. | 2005 Sep |
Patents
Sample Use Guides
SATIVEX® is provided as a buccal spray in a 5.5 ml vial, with each 100 microlitre spray providing 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). In patients with multiple sclerosis, the median daily dosage of SATIVEX® in the extension phase of the 4-week clinical trial was 5 sprays per day. The majority of patients required 12 sprays or less; dosage should be adjusted as needed and tolerated. There is limited experience with doses higher than 12 sprays per day. Some patients may require and may tolerate a higher number of sprays. In patients with pain in cancer, the median daily dosage of SATIVEX® was 8 actuations (sprays).
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27932991
in vitro pre-treatment of Human Gingival Mesenchymal Stem Cells with 5 uM Cannabidiol (CBD) can influence their expression profile
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:30:49 GMT 2023
by
admin
on
Sat Dec 16 16:30:49 GMT 2023
|
Record UNII |
19GBJ60SN5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/17/1959
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
471815
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
510716
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
NCI_THESAURUS |
C274
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
914322
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
NCI_THESAURUS |
C1742
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
444814
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
409313
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
860921
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
609617
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
DSLD |
3397 (Number of products:162)
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
617417
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
521416
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
WHO-ATC |
N03AX24
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
452614
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
620417
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
696519
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
734820
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
806620
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
545316
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
482315
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
656618
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
736020
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
439414
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
819221
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
538916
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
WHO-ATC |
N02BG10
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
763820
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
486115
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
610117
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
488315
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
421213
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
628818
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
549616
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
498215
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
438214
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
668918
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
734620
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
860821
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
450814
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
||
|
NCI_THESAURUS |
C105578
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2045371
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
1089149
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL190461
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
Cannabidiol
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
CD-48
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
SUB26600
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
C118452
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
CANNABIDIOL
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
69478
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
1089161
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
ALTERNATIVE | |||
|
10423
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
DB09061
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
19GBJ60SN5
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
5288
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
19GBJ60SN5
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
13956-29-1
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
644019
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
DTXSID00871959
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
100000091179
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
D002185
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | |||
|
m3020
Created by
admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->INVERSE AGONIST |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
Cannabidiol Class | Anxiolytic Antipsychotic | Analgesic | Anti-inflammatory | Antioxydant | Antispasmodic
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> ACTIVATOR |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
BINDER->LIGAND |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> INHIBITOR |
Responsible for a drug interaction with clobazam. Mean increase in clozabam and N-desmethylclozabam levels was 60% and 500%, respectively, after 4 weeks of concomitant therapy.
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET->INVERSE AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE INACTIVE -> PARENT |
The major circulating metabolites include 7-carboxy-cannabidiol (7-COOH-CBD), which was approximately 40-fold higher than the parent.
MAJOR
|
||
|
METABOLITE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE ACTIVE -> PARENT |
The major circulating metabolites include 7-hydroxy-cannabidiol (7-OH-CBD), which was approximately 38% of the parent based on AUC of cannabidiol.
MAJOR
|
||
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
TWICE-DAILY DOSING FOR 7 DAYS |
|
||